Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling

The present study explored the feasibility of a differential setup for the in situ perfusion technique with mesenteric cannulation in rats to assess drug interactions at the level of intestinal absorption. In contrast to the classic, parallel in situ perfusion setup, the differential approach aims to identify intestinal drug interactions in individual animals by exposing the perfused segment to a sequence of multiple conditions. First, the setup was validated by assessing the interaction between the P‐glycoprotein (P‐gp) inhibitor verapamil and the transport probes atenolol (paracellular transport), propranolol (transcellular) and talinolol (P‐gp mediated efflux). While transport of atenolol and propranolol remained constant for the total perfusion time (2 h), a verapamil‐induced increase in talinolol transport was observed within individual rats (between 3.2‐ and 5.2‐fold). In comparison with the parallel setup, the differential in situ perfusion approach enhances the power to detect drug interactions with compounds that exhibit strong subject‐dependent permeability. This was demonstrated by identifying an interaction between amprenavir and ketoconazole (P‐gp and CYP3A inhibitor) in five out of seven rats (permeability increase between 1.9‐ and 4.2‐fold), despite high inter‐individual differences in intrinsic permeability for amprenavir. In combination with an increased throughput (up to 300%) and a reduced animal use (up to 50%), the enhanced power of the differential approach improves the utility of the biorelevant in situ perfusion technique with mesenteric blood sampling to elucidate the intestinal interaction profile of drugs and drug candidates. Copyright © 2010 John Wiley & Sons, Ltd.

[1]  Leslie Z. Benet,et al.  The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.

[2]  P. Annaert,et al.  INTESTINAL PERFUSION WITH MESENTERIC BLOOD SAMPLING IN WILD-TYPE AND KNOCKOUT MICE , 2009, Drug Metabolism and Disposition.

[3]  J. Dressman,et al.  Cytochrome P450-mediated metabolism in the human gut wall. , 2009, The Journal of pharmacy and pharmacology.

[4]  P. Artursson,et al.  Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  P. Sinko,et al.  Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats , 2008, Drug Metabolism and Disposition.

[6]  C. Xia,et al.  Evaluation of drug-transporter interactions using in vitro and in vivo models. , 2007, Current drug metabolism.

[7]  J. Tack,et al.  Parallel Monitoring of Plasma and Intraluminal Drug Concentrations in Man After Oral Administration of Fosamprenavir in the Fasted and Fed State , 2007, Pharmaceutical Research.

[8]  Shufeng Zhou,et al.  Role of P-glycoprotein in the Intestinal Absorption of Glabridin, an Active Flavonoid from the Root of Glycyrrhiza glabra , 2007, Drug Metabolism and Disposition.

[9]  M. Wempe,et al.  Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Patrick Augustijns,et al.  Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. , 2006, Journal of pharmaceutical sciences.

[11]  P. Augustijns,et al.  Sulfasalazine transport in in‐vitro, ex‐vivo and in‐vivo absorption models: contribution of efflux carriers and their modulation by co‐administration of synthetic nature‐identical fruit extracts , 2005, The Journal of pharmacy and pharmacology.

[12]  M. Varma,et al.  Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. , 2005, Journal of pharmaceutical sciences.

[13]  P. Augustijns,et al.  HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. , 2004, Journal of pharmaceutical and biomedical analysis.

[14]  P. Sinko,et al.  Intestinal drug transporters: in vivo function and clinical importance. , 2004, Current drug metabolism.

[15]  Leslie Z Benet,et al.  In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model , 2003, Journal of Pharmacology and Experimental Therapeutics.

[16]  P Langguth,et al.  Intestinal drug efflux: formulation and food effects. , 2001, Advanced drug delivery reviews.

[17]  P. Langguth,et al.  Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  Lawrence X. Yu,et al.  Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1 , 1999, Pharmaceutical Research.

[19]  P. Sinko,et al.  Oral absorption of the HIV protease inhibitors: a current update. , 1999, Advanced drug delivery reviews.

[20]  D. Fleisher,et al.  Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration , 1999, Clinical pharmacokinetics.

[21]  P. Annaert,et al.  In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism , 2008 .

[22]  W. Charman,et al.  The Mucosa of the Small Intestine , 2002, Clinical pharmacokinetics.